**6. Conclusion**

Antiplatelet agents have been widely utilized in patients with acute coronary syndrome for decades and are increasingly valued for their antithrombotic as well as anti-inflammatory characteristics. DAPT has been shown to be effective in improving the clinical outcomes of patients with ACS or PCI but is associated with high bleeding risk. Recent guidelines have been proposed not only to help reduce the tendency of bleeding in DAPT patients but also to ultimately improve patient overall quality of life.
